Non-toxic and short treatment with gemcitabine inhibits in vitro migration of HT-1080 cells

被引:2
作者
Alcouffe, C
Boutonnat, J
Clément-Lacroix, J
Mousseau, M
Ronot, X
机构
[1] Ecole Prat Hautes Etud, Lab Dynam Cellulaire, Grenoble, France
[2] CNRS, UMR 5525, Equipe Dynacell, Grenoble, France
[3] CHU Grenoble, Med Oncol Serv, F-38043 Grenoble, France
关键词
antimetabolite; cytometry; metastasis; proliferation;
D O I
10.1097/00001813-200409000-00010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gemcitabine has demonstrated clinical activity in solid tumors. Several in vitro studies were carried out regarding its metabolism, toxicity and cell cycle effects, but none was done on the anti-metastasis potential of the drug. We sought to determine the effect of gemcitabine concentrations on migration velocity of HT-1080 cells at concentrations which do not alter cell cycle progression and proliferation. Cells were treated for 1 or 5 h at IC10-70 Of gemcitabine in order to estimate its effects on viability, proliferation and migration capacity using flow cytometry and microscopy imaging, respectively. The gemcitabine treatment for 1 h had no effect on cell proliferation, viability, cycle or migration on HT-1080 cells. Even though the 5 h of exposure at IC10, IC20 and IC50 concentrations did not affect cell viability, proliferation and cell cycle repartition, the mean velocity of HT-1080 dramatically decreased by 50 and 30%, respectively. Gemcitabine at IC70 concentrations for 5 h of exposure first induced a time course inhibition of proliferation, together with a decrease in viability and altered cell morphology, and then inhibited cell migration by 50%. These data suggest the possibility to couple the anti-migratory Property of gemcitabine with the known anti-tumoral effect in the treatment of tumors with high metastatic potential. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:803 / 807
页数:5
相关论文
共 26 条
[1]   Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck [J].
Aguilar-Ponce, JL ;
Granados-García, M ;
Villavicencio, V ;
Poitevin-Chacón, A ;
Green, D ;
Dueñas-González, A ;
Herrera-Gómez, A ;
Luna-Ortiz, K ;
Alvarado, A ;
Martínez-Said, H ;
Castillo-Henkel, C ;
Segura-Pacheco, B ;
De la Garza, J .
ANNALS OF ONCOLOGY, 2004, 15 (02) :301-306
[2]   Optimized fluorescent probe combinations for evaluation of proliferation and necrosis in anthracycline-treated leukaemic cell lines [J].
Boutonnat, J ;
Barbier, M ;
Muirhead, K ;
Mousseau, M ;
Ronot, X ;
Seigneurin, D .
CELL PROLIFERATION, 1999, 32 (04) :203-213
[3]   THE INFLUENCE OF THE SCHEDULE AND THE DOSE OF GEMCITABINE ON THE ANTITUMOR EFFICACY IN EXPERIMENTAL HUMAN CANCER [J].
BOVEN, E ;
SCHIPPER, H ;
ERKELENS, CAM ;
HATTY, SA ;
PINEDO, HM .
BRITISH JOURNAL OF CANCER, 1993, 68 (01) :52-56
[4]   Cell cycle effects of gemcitabine [J].
Cappella, P ;
Tomasoni, D ;
Faretta, M ;
Lupi, M ;
Montalenti, F ;
Viale, F ;
Banzato, F ;
D'Incalci, M ;
Ubezio, P .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (03) :401-408
[5]  
Haga A, 1997, CANCER BIOCHEM BIOPH, V15, P275
[6]  
HEINEMANN V, 1992, CANCER RES, V52, P533
[7]  
HEINEMANN V, 1988, CANCER RES, V48, P4024
[8]  
HEINEMANN V, 1995, SEMIN ONCOL, V22, P11
[9]  
HUANG P, 1991, CANCER RES, V51, P6110
[10]   Gemcitabine: A cytidine analogue active against solid tumors [J].
Hui, YF ;
Reitz, J .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (02) :162-170